Tonix Pharmaceuticals Announces Two Publications of Data in American Journal of Transplantation Showing TNX-1500 (anti-CD40L mAb) Prolongs Nonhuman Primate Renal and Heart Allograft SurvivalGlobeNewsWire • 04/17/23
Tonix Pharmaceuticals Presents Data from its Vaccine Development Program at the World Vaccine CongressGlobeNewsWire • 04/06/23
Tonix Pharmaceuticals Announces Poster Presentations at the American Association for Cancer Research Annual Meeting 2023GlobeNewsWire • 04/05/23
Tonix Pharmaceuticals Presents Positive Efficacy and Safety Data from Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia at the 5th International Congress on Controversies in FibromyalgiaGlobeNewsWire • 03/30/23
Tonix Pharmaceuticals Announces Oral Presentations at the World Vaccine CongressGlobeNewsWire • 03/27/23
Tonix Pharmaceuticals exec presents data on Prader-Willi Syndrome drug at rare disease conferenceProactive Investors • 03/23/23
Tonix Pharmaceuticals Presents Non-Clinical Data on TNX-2900 for the Potential Treatment of Hyperphagia in Adolescents and Young Adults with Prader-Willi Syndrome at the Rare Disease Innovation and Partnership SummitGlobeNewsWire • 03/23/23
Tonix Pharmaceuticals Announces Oral Presentation and Poster at the 5th International Congress on Controversies in FibromyalgiaGlobeNewsWire • 03/23/23
Tonix Pharmaceuticals Announces Presentation at the Rare Disease Innovation and Partnership SummitGlobeNewsWire • 03/16/23
Tonix Pharmaceuticals Initiates Enrollment in Phase 2 ‘UPLIFT' Study of TNX-601 ER (Tianeptine Hemioxalate Extended-Release Tablets) for the Treatment of Major Depressive Disorder (MDD)GlobeNewsWire • 03/16/23
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational HighlightsGlobeNewsWire • 03/13/23
Tonix Pharmaceuticals Announces Results from a Preclinical Study of Murine TNX-1700 Presented in a Poster at the Keystone Symposia, “Cancer Immunotherapy: Mechanisms of Response Versus Resistance”GlobeNewsWire • 03/07/23
Tonix Pharmaceuticals obtains exclusive license to develop fully human and murine anti-SARS-CoV-2 monoclonal antibodiesProactive Investors • 02/13/23
Tonix Pharmaceuticals Announces Exclusive License of Potential Therapeutic or Preventative Fully Human and Murine Anti-SARS-CoV-2 Monoclonal AntibodiesGlobeNewsWire • 02/13/23
Tonix Pharmaceuticals Announces Publication of Paper in Viruses Highlighting the Company's Development of a Vaccine to Protect Against Monkeypox and Smallpox (TNX-801)GlobeNewsWire • 02/09/23
Tonix Pharmaceuticals Initiates Enrollment in Phase 2 ‘PREVENTION' Study of Potentiated Intranasal Oxytocin (TNX-1900) for the Prevention of Migraine Headaches in Chronic MigraineursGlobeNewsWire • 02/06/23
Tonix Pharmaceuticals Announces Acquisition of Preclinical Infectious Disease Portfolio from Healion Bio, Inc.GlobeNewsWire • 02/02/23
Tonix Pharmaceuticals Announces Research Agreement with University of Maryland, Baltimore, to Study TNX-1500 (Fc-modified anti-CD40L mAb) for the Prevention of Rejection in Heart Xenograft Transplantation in AnimalsGlobeNewsWire • 02/01/23
Tonix Pharmaceuticals Announces Presentation of Clinical and Non-Clinical TNX-1900 Data at the Annual Headache Cooperative of the Pacific (HCOP) Winter ConferenceGlobeNewsWire • 01/31/23
Tonix Pharmaceuticals Announces Presentation of Licensed Antiviral Drug Technology at the 2nd Wnt & β-catenin Targeted Drug Development ConferenceGlobeNewsWire • 01/26/23
